Bevacizumab for adults with symptomatic, untreatable brain AVMs
Treatments studied
Part of Brain & nervous system, Genetic & congenital, Heart & circulation clinical trials.
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have a symptomatic brain AVM that is large or complex (grades III, IV, or V) and causing problems like headaches, seizures, thinking issues, or weakness.
- Your symptoms are significant enough to show improvement, as measured by certain tests or scores.
- Your symptoms are not just from a past brain bleed and are disabling in daily life.
- You have been told that standard treatments (surgery, embolization, or radiation) are not an option for you.
- You have normal bone marrow, liver, and kidney function (checked by blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a simple blood test can detect genetic changes in brain arteriovenous malformations (AVMs). If successful, it may help guide treatment without needing a tissue biopsy.
This study looks for blood test markers that may predict who survives at 6 months after starting bevacizumab for glioblastoma that has come back. It does not aim to cure the cancer by itself, but to improve doctors’ ability to choose the most helpful treatment plan.
This trial uses a blood test to look for genetic mutations in brain arteriovenous malformations (bAVMs). It may help doctors understand these lesions better and guide treatment.
This trial tests if injecting a medication called bevacizumab directly into certain hard-to-treat brain blood vessel malformations can help. It is for adults with large or complex malformations that have already bled or caused serious symptoms and cannot be removed with standard surgery or procedures.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
This trial tests if injecting bevacizumab into the artery that supplies the covering of the brain can help treat chronic subdural hematoma (a slow-growing collection of blood on the brain's surface). It may offer an alternative to surgery for some patients.
Hear when a new Cerebral AV Malformation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.